Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Beyond the plateau: defining cure and charting the next decade in follicular lymphoma: redefining cure in follicular lymphoma.

Created on 11 Nov 2026

Authors

Qinghua Ke, Shiqiong Zhou

Published in

Medical oncology (Northwood, London, England). Volume 43. Issue 12. Nov 10, 2026. Epub Nov 10, 2026.

Abstract

The 15-year follow-up of the SWOG S0016 trial provides pivotal evidence that chemoimmunotherapy can achieve long-term cure in a substantial subset of patients with advanced follicular lymphoma (FL). Using a relative-survival cure model, the study estimates a cured fraction of 42% (35% for R‑CHOP), with annual relapse rates declining to 0.6% beyond 15 years. These findings challenge the traditional narrative of FL as incurable and support the de-escalation of surveillance in long-term survivors. Notably, the trial's R‑CHOP arm achieved a 15-year PFS of 34%, comparable to outcomes with rituximab maintenance in other studies, although careful cross‑trial comparisons are limited by differences in patient selection, staging, and follow‑up methodology. The superior long‑term PFS observed with CHOP plus radioimmunotherapy suggests that deeper initial remissions may yield durable disease control, though this did not translate into an overall survival benefit, and the increased rate of myeloid neoplasms limits its clinical applicability. Unanswered questions remain regarding the role of minimal residual disease (MRD) as a surrogate for cure, the impact of novel frontline agents (including obinutuzumab‑based and bendamustine‑containing regimens), and the integration of molecular subtypes into cure definitions. The estimated cure fraction remains a population‑level statistical construct and should not be directly applied to individual patients without further validation. These results reframe the possibility of cure in FL and emphasize the need for extended follow‑up in trials of emerging therapies.

PMID:
43007590
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement